Results 91 to 100 of about 2,405,537 (303)

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

open access: yesMolecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric   +10 more
wiley   +1 more source

Results of the Patient Safety Authority’s 2018 Process Measures Survey

open access: yesPatient Safety, 2019
Improving patient safety is an ongoing journey that benefits from periodic assessment to recognize, reward, and redirect efforts. As an independent, nonregulatory state agency, the Patient Safety Authority (PSA) is uniquely positioned to both conduct ...
Michelle Bell, Kim Liberatore
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

open access: yesMolecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena   +15 more
wiley   +1 more source

We All Win When Patients Speak Up: A Conversation With Patient Advocate Lisa Rodebaugh; Executive Director of the Patient Safety Authority (PSA), Regina Hoffman; and PSA director of Engagement, Caitlyn Allen.

open access: yesPatient Safety, 2021
Lisa Rodebaugh: My husband, Bill, and I can rattle off our stories in two minutes or less—stories from having five children, each with varying medical and developmental needs that presented far differently from what specialists typically see.
Lisa Rodebaugh   +2 more
doaj  

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

open access: yesMolecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor   +2 more
wiley   +1 more source

Newborn Falls in Pennsylvania: An Analysis of Recent Events and a Review of Prevention Strategies

open access: yesPatient Safety, 2019
Despite increasing recognition of the potential risks associated with in-hospital newborn falls among health professionals, new parents are frequently unaware of the possibility of dropping their newborn, especially in the hospital. Although most newborn
Elizabeth Kukielka, Susan C. Wallace
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Risk of Medication Errors With Infusion Pumps: A Study of 1,004 Events From 132 Hospitals Across Pennsylvania

open access: yesPatient Safety, 2019
The risk of medication errors with infusion pumps is well established, yet a better under-standing is needed of the scenarios and factors associated with the errors.
Matthew A. Taylor , Rebecca Jones
doaj   +1 more source

Home - About - Disclaimer - Privacy